
100.98 Delayed Data As of Jan 15 | ![]() Today’s Change | 43.29 Today|||52-Week Range 125.61 | -9.96% Year-to-Date |
Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD Jan 15 / Zacks.com - Paid Partner Content | 3 Biotech Stocks Worth Adding to Your Portfolio in 2021 Jan 08 / Zacks.com - Paid Partner Content |
Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija Jan 14 / Zacks.com - Paid Partner Content | Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug Jan 05 / Zacks.com - Paid Partner Content |
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic Jan 13 / Zacks.com - Paid Partner Content | Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study Jan 04 / Zacks.com - Paid Partner Content |
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day Jan 11 / Zacks.com - Paid Partner Content |
Previous close | 102.51 |
Today’s open | 102.74 |
Day’s range | 100.65 - 102.74 |
Volume | 17,505 |
Average volume (3 months) | 502,903 |
Market cap | $5.6B |
Earnings growth (last year) | -34.76% |
Earnings growth (this year) | +175.53% |
Earnings growth (next 5 years) | +34.00% |
Revenue growth (last year) | +49.39% |
P/E ratio | 17.2 |
Price/Sales | 57.61 |
Price/Book | 10.69 |
Today’s change | Today’s % change | |
---|---|---|
EBSEmergent BioSolution... | +0.24 | +0.23% |
---- | ||
EIDXEidos Therapeutics I... | -2.00 | -1.56% |
HALOHalozyme Therapeutic... | +0.39 | +0.83% |
Next reporting date | March 5, 2021 |
EPS forecast (this quarter) | -$1.60 |
Annual revenue (last year) | $66.5M |
Annual profit (last year) | -$347.7M |
Net profit margin | -522.75% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |